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regulated by wild and mutant HBx, demonstrated a lower
level in the LO2/HBx-d382 cell. Further characterization of
miR-338 3p revealed that it negatively regulated cellular
proﬁleration. Cell cycle analysis showed that miR-338 3p
induced cell cycle arrest at the G1/S phase. A dual-
luciferase reporter assay demonstrated that the 3′UTR of
CyclinD1 were directly bound to miR-338 3p and western
blotting analysis further indicated that miR-338 3p down-
regulated the expression of CyclinD1.
Conclusion: This study demonstrates that HBx can
inﬂuence cellular miRNA expression. The deregulation of
the expression of miR-338 3p by HBx may represent a
potential novel pathway which HBx acts to deregulate cell
proliferation leading to hepatocarcinogenesis.
PP-106 Relationship between HBsAg, HBcAg expression
and serum HBV DNA level in 140 patients with
chronic hepatitis B
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Afﬁliated Hospital of Sun Yat-sen University, China
Objective: The aim of this study was to investigate the
relationship between HBsAg, HBcAg expression and serum
HBV DNA level.
Methods: The expression of HBsAg, HBcAg in the livers
of 140 patients with chronic hepatitis B was detected by
immunohistochemistry. And the level of serum hepatitis B
virus DNA (HBV DNA) was tested. Statistical signiﬁcance was
assessed using One-Way analysis of variance (ANOVA).
Results: Serum HBV DNA level in 13 patients with
HBsAg ( ~±), 108 patients with (+~++) and 19 patients
with (+++~++++) was 5.313±1.874 copies log10/ml,
6.010±2.016 copies log10/ml and 5.664±1.548 copies
log10/ml respectively (P= 0.408). Serum HBV DNA level in
42 patients with HBsAg ( ~±), 79 patients with (+~++)
and 19 patients with (+++~++++) was 5.886±1.997 copies
log10/ml, 5.968±2.020 copies log10/ml and 5.634±1.551
copies log10/ml respectively (P= 0.800).
Conclusions: The expression of HBsAg, HBcAg in the liver
does not correlate with serum HBV DNA level.
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Objectives: To analyze the causes of the patients with
chronic Hepatitis B without taking antiviral therapy and the
strategies of dealing with it.
Method: We make long-termed observation on the patients
with chronic Hepatitis B Virus (HBV) infection, who were
voluntarily to be followed up in our clinic department, and
analyze statistically the objective and subjective causes of
patient without taking antiviral therapy.
Results: In total eligible 951 cases, 424 cases didn’t
receive the antiviral therapy. 105 out of 424 cases had the
indications of the antiviral therapy (105/424, 24.8%), the
other 319 cases had no indications of the therapy (319/424,
75.2%). The ratio of female (124/202, 61.4%) who didn’t
get the antiviral therapy was signiﬁcant higher than that
of male (300/749, 40.0%). 49 out of 105 cases who had
the indications of the antiviral therapy worried about the
unhealthful effect on their fertility by the antiviral drugs
and put off antiviral therapy (49/105, 46.7%); 31out of
105 cases could not pay for the antiviral therapy (31/105,
29.5%); 19 out of 105 cases queried the safety of the
antiviral drugs and uncertainty of course of the treatment
(19/105, 18.1%). 6 out of 105 cases were because of poor
compliance (6/105, 5.7%).
Conclusions: No antiviral indications was the main cause
of the untreated group. The causes of that patients
with indications didn’t receive antiviral therapy were
that worrying about their fertility, fees of the treatment
hard to bear, querying the safety of the antiviral drugs
and uncertainty of course of the treatment, and poor
compliance. Formal long-termed follow up by the clinicians,
good communications between clinicians and patients and
health education might improve the effects of anti-HBV
treatment.
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Objective: To investigate the relationship between serum
HBV DNA loads and liver pathological changes in the patients
with chronic hepatitis B.
Methods: The relationship among HBV DNA loads, live
histological inﬂammation grades and ﬁbrosis stages of
158 cases was analyzed.
Results: The serum HBV DNA loads in HBeAg-positive group
with inﬂammation grades G0 1 (6 patients), G2 (74 patients)
and G3 4 (25 patients) were 5.580±1.098 copies log10/ml,
6.520±2.004 copies log10/ml and 6.950±1.467 copies
log10/ml respectively. There was no signiﬁcant difference
in patients of three inﬂammation grades (P= 0.250). The
serum HBV DNA loads in HBeAg-positive group with liver
tissues ﬁbrosis stages of S0 1 (23 patients), S2 (56 patients),
S3 4 (26 patients) were 6.599±1.832 copies log10/ml,
6.559±2.012 copies log10/ml, 6.562±1.601 copies log10/ml
respectively, the difference was not signiﬁcant (P= 0.996).
The serum HBV DNA loads in HBeAg-negative group with
inﬂammation grades G0 1 (8 patients), G2 (17 patients)
and G3 4 (28 patients) were 2.132±1.875 copies log10/ml,
4.745±2.250 copies log10/ml and 5.581±2.305 copies
log10/ml respectively. The serum HBV DNA level in patients
with G2 and G3 4 inﬂammation grades was signiﬁcant
higher than in patients with G0 1 inﬂammation grades
(P= 0.001). The serum HBV DNA loads in HBeAg-negative
group with liver tissues ﬁbrosis stages of S0 1 (10 patients),
S2 (45 patients), S3 4 (18 patients) were 2.689±3.225 copies
log10/ml, 5.127±1.833 copies log10/ml, 5.375±2.410 copies
log10/ml respectively. The serum HBV DNA level in patients
with ﬁbrosis stages of S2 and S3 4 was signiﬁcant higher than
in patients with ﬁbrosis stages of S0 1 (P = 0.005).
Conclusions: The serum HBV DNA level does not correlate
with the inﬂammation grades and ﬁbrosis stages of liver
tissues in HBeAg-positive patients. The serum HBV DNA
loads display a positive correlation with the inﬂammation
grades and ﬁbrosis stages of liver tissues in HBeAg-negative
patients.
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Objectives: Hepatitis B Virus (HBV) infection is a primary
risk factor for hepatocellular carcinoma (HCC), the ﬁfth
most frequent cancer, worldwide. The present study was
undertaken to analyze the association of IL-6 ( 572) and
S76 Abstracts, 5th DICID
( 597) polymorphisms and IL-6 levels with hepatitis B virus
related HCC risk in Indian population.
Methods: Five groups of subjects were enrolled viz. control
(n = 100), HBV-carriers (n = 60), chronic active HBV (n = 60),
HBV-cirrhotic (n = 60) and HBV-related HCC (n = 53). PCR-
RFLP was performed to study various polymorphic forms of
IL-6 and levels in PBMCs were estimated by ELISA. Genotype
distributions were compared using chi square analysis and
the odds ratios (ORs) and 95%CI were calculated to express
the relative risk.
Results: In IL-6 ( 572), the GC genotype, was in negative
association (p < 0.001) with HCC, among controls, while it
was a signiﬁcant risk factor (p < 0.001) for the same, among
HBV-carriers. In contrast, the CC genotype was a risk factor
(p < 0.001) for progression the disease to cirrhosis among
controls and HBV-carriers (OR: 3.2 and 4.0 respectively).
In case of IL-6( 597), GA genotype signiﬁcantly increased
(p < 0.001) HCC risk, both among controls and HBV-carriers.
The IL-6 levels were found to be signiﬁcantly lower in all the
diseased groups, with reference to controls. However, levels
were signiﬁcantly higher in cirrhotic group when compared
with the carrier and active hepatitis group. Moreover, in
both IL-6( 572) and ( 597) heterozygotes were found to
have lower IL-6 levels as compared to those having wild
genotypes.
Conclusions: Polymorphic forms of IL-6 and basal IL-6
levels share a strong association with HBV-HCC risk in
Indian population and thus should be further evaluated
as candidate genes to determine individual susceptibility
for the same.
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Objectives: Evaluate the efﬁcacy of Tiaoganjanpihexue (a
traditional Chinease medicine term) CHM-prescription for
treating a 31-year-old female HBeAg(+) chronic hepatitis B
Chinese patient with suboptimal response to Adefovir
Dipivoxil (AD) for 63 weeks switch to AD + lamivudine (LVD)
for 18 weeks, and to AD for 45 weeks, and to Telbivudine
(TEB) for 24 weeks. Modeling the dynamics of the anti-HBV
infection treatments.
Methods: During 2007 2010, the patient was treated
by AD, AD+LVD, AD and TEB continuously. Her baseline
characteristics were HBV DNA = 3.48×107 cps/ml, ALT
= 103.2 I/U, HBeAg = 1.400 S/CO, Anti-HBe = 0.213S/CO
and those at week 150 were HBV DNA <1000 cps/ml,
ALT <14 I/U (over 100 weeks), HBeAg = 3.840S/CO, Anti-
HBe = 1.061S/CO. After 16 weeks’ stopping treatment, her
HBV DNA was returned to 6.8×103 and other characteristics
were almost the same as those at week 150. Using the CHM
Tiaoganjanpihexue (consisting of 21 ingredients) treated the
patient, two times daily and decoction after meals.
Results: After 4 weeks’ treatment her HBeAg and anti-
HBe reduced to 0.850S/CO and 0.528S/CO. Following
21 weeks’ addtional treatments, her HBeAg had been kept
seroconversion and HBV DNA reduced to 1.40×103 cps/ml.
During the 25 week’s Tiaoganjanpihexue therapy, her mean
ALT = 19.03 I/U. A mathematical new model is introduced to
model the dynamics of the anti-HBV infection treatment.
The simulated curve is in good agreement with the clinic
tested patient’s HBV DNA.
Conclusions: The CHM Tiaoganjanpihexue has a speciﬁc
function that is able to activate patient’s immune function
to suppress HBV directly but not injure the patient’s
hepatocytes.
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PP-111 Hepatitis B virus (HBV) subgenotypes and
mutations in core promoter and precore/core
and their clinical implications in Xinjiang Uighur
patients
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Objective: To detecte HBV subtypes, mutation of core
promoter and precore/core and clinical features among
Xinjiang Uygur patients with chronic HBV infection.
Methods: PCR-RFLP was used to detect the subtypes, core
promoter and precore/core of HBV in 109 Uygur patients
with chronic HBV, and analyses of the relationship between
mutation and clinical features.
Results: In 109 Uygur patients with chronic HBV group, there
were 9 cases with HBV genotype B infection who were HBV
Ba subtype, 50 cases with HBV genotype C and 27 cases
with C1 subtype i, 23 cases with C2 subtype, 32 cases
with C/D recombinant i, 18 cases with HBV genotype D
infection. According to the progress of the HBV infection,
G1896A mutation in HBV precore or core region had no
signiﬁcant difference in chronic hepatitis B and cirrhosis,
but A1762T/G1764A mutation in the HBV subtype C1 and C2
and i Ba have signiﬁcantly increased in cirrhosis.we fund that
A1762T/G1764A mutation in HBV C/D recombinant infection
is low.
Conclusion: Uygur patients with CHB have more HBV C/D
recombinant, and C1 subtype infection. A1762T/G1764A
mutation in the HBV subtype C1 and C2 subtypes have
signiﬁcantly increased.
PP-112 Genotyping of hepatitis B virus in 280 patients
infected with hepatitis B Virus and its clinical
signiﬁcance
W.D. Li1 *, J.L. Chen1, C.Q. Li1. 1Beijing DiTan Hospital,
Capital Medical University, China
Objective: Previous studies showed that HBV genotype
correlated with HBV transmission, clinical disease spectra,
progression, prognosis, antiviral effect, etc. This study
is aimed to evaluate the clinical signiﬁcance of HBV
genotype.
Methods: HBV genotypes were analyzed in 280 patients
infected with hepatitis B virus. Liver function, HBV markers
including PreS1, HBV DNA levels and T cell subsets of these
patients were also measured.
Results: HBV genotyping had a geographical distribution.
Genotype C was mainly prevalent in patients from north
china while Genotype B from south china. In the progression
of asymptomatic carrier or acute hepatitis to chronic
hepatitis, liver cirrhosis and liver cancer, genotype C
increased while genotype B decreased. Genotype C and
genotype BC showed lower levels in prealbum (Pre-A)
and album (ALB) and lower ratio of album to globulin
(A/G) than genotype B (P= 0.02, P= 0.03, P= 0.01 and
P= 0.005, P= 0.001, P< 0.001, respectively), but showed
higher levels in globulin (GLO) than genotype B (P< 0.001
and P= 0.01, respectively). Genotype C showed lower levels
in cholinesterase (CHE) than genotype B (P= 0.007). There
